Newsletter

Watch List for Thursday 3-15-2012 - Email Ad

More on BMGP

Some biotech companies have seen tremendous gains in a few months. Gains as high as 500% or even 1000%.  Sounds crazy but actually very common for the Biopharma industry.

When one of these companies find a cure for a disease or gets some sort of FDA approval, the stock usually skyrockets.

Will BMGP ever be shot into the spotlight?  Who knows, but the company does have a product that could be revolutionary!

BMGP has a product that could actually raise the benchmark for the biotech industry.  Their machines are not approved in the US yet.  Which actually works to your advantage, because it gives you ample time to do your research!

There are so many scary and sometimes deadly diseases in this world. This includes HIV/Aids, hepatitis, malaria, and tuberculosis. It is critical for these diseases to be detected as early as possible. The sooner they are caught, the quicker doctors can leap to action with the right medicines or vaccines.

Diagnostic screening is critical in the healthcare industry and for blood banks.

Yes, blood blanks. Imagine how much blood goes through blood banks. They have to make sure that blood is not infected with anything deadly or dangerous to other beings.

Many blood centers have equipment that can detect HIV and hepatitis B before the viruses show up in normal blood tests. However, it costs a lot of money to do this!

It has been said that nationally, blood banks screen 14 million units of blood annually for seven types of viruses for a total of 91 million tests per year.

BMGP has designed a system that can test for all the eight viruses that are currently being screened for in each unit of blood, in a SINGLE ASSAY, thus greatly reducing the cost to analyze incoming blood!

So many diseases are endemic to developing countries. The kind of diagnostics system that BMGP has could potentially save millions of lives!

BMGP's HTS-MTP system is designed to detect the virus and count the viral load in a matter of minutes, and has the capabilities of screening many more assays per hour, at a fraction of the cost of current technology!

No current screening, or confirmatory tests, have the ability to measure viral load; a critical measurement in developing drugs and vaccines and determining the effectiveness of health care treatments.

The system focuses on real-time testing for the actual presence of the virus/ toxin/ disease itself, and not for antibodies produced by the body's immune system which may take anywhere from weeks to months to appear.

Detection in minutes compared to weeks or months can mean everything to someone who has a disease and needs the proper medicine.

BMGP sits on a threshold of tremendous promise in saving lives while making money at the same time.

There are millions of people infected across the world with diseases like Malaria and Tuberculosis.

Each year, there are approximately 350–500 million cases of malaria, killing between one and three million people, the majority of whom are young children in sub-Saharan Africa. Ninety percent of malaria-related deaths occur in sub-Saharan Africa!

Although many are under development, the challenge of producing a widely available vaccine that provides a high level of protection for a sustained period is still to be met.

A third of the world's population are thought to be infected with M. tuberculosis, and new infections occur at a rate of about one per second!

In 2007 there were an estimated 13.7 million chronic active cases, 9.3 million new cases, and 1.8 million deaths, mostly in developing countries.

HIV infection in humans is considered a pandemic by the World Health Organization. Unfortunately most people infected with HIV will eventually develop AIDS. An estimated 34 million people were living with HIV/AIDS in 2010. During that yere there were 2.7 million new HIV infections and 1.8 million people died from AIDS!

BMGP is developing test machines for cholera, HIV, malaria and hepatitis B. Think of the possibilities!

BMGP is positioning itself to perform clinical trials in Mexico, Kenya, India and China in the fourth quarter of 2010 followed by trials in the US and Europe. Biomagnetics hopes to have products in use in those countries by early 2011, followed by US and European sales sometime in 2012, pending successful financing and approvals.

For more information on BMGP, visit their website at: www.biomagneticsbmgp.com      Please do your due diligence and consult with your own financial professional.

*********************************************************

PLEASE NOTE WELL: This report/release/advertisement is a commercial advertisement and is for general information purposes only.  We are engaged in the business of marketing and advertising companies for monetary compensation.  Coolpennystocks.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice.  We do no not buy or sell and we do not receive shares in any of our compensated profiled companies. The disclaimer is to be read and fully understood before using our site, or joining our email list.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.  All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Coolpennystocks sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Coolpennystocks Network or an offer or solicitation to buy or sell any security.  Viewers should always consult with a licensed securities professional before making any type of investment decision.  Coolpennystocks.com does not provide trading, investment or tax advice, and readers shall not rely on statements by Coolpennystocks.com employees which purport to provide such advice.  Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk.  Full disclaimer can be read at http://www.Coolpennystocks.com/disclaimer.htm

Release of Liability: Through use of this website or email viewing or using you agree to hold Coolpennystocks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur.  The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.  Coolpennystocks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Coolpennystocks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.  None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead Coolpennystocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Coolpennystocks is compliant with the Can Spam Act of 2003.  Coolpennystocks.com does not offer such advice or analysis, and Coolpennystocks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.

Coolpennystocks.com has been compensated by a third party ATG Inc. thirty eight thousand dollars for a one week BMGP advertising services contract.  Coolpennystocks.com does not own any shares of BMGP.  The third party, may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

All direct and third party compensation received will be disclosed within each individual email in accordance with section 17(b) of the 1 9 3 3 Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.  Coolpennystocks.com has not investigated the background of the third party, the hiring company. Anyone viewing our website and advertisement should assume that the hiring party and affiliates of the hiring party own shares of the profiled company of which they plan to liquidate, further understanding that the liquidation of those shares will most likely impact the share price of the profiled company negatively. 

Some of the content in this release contains forward-looking information within the meaning of Section 27 A of the Securities Act of 1 993 and Section 21 E of the Securities Exchange Act of 1 934 including statements regarding expected continual growth of the profiled company and the value of its securities.  In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1 995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results.  The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, Coolpennystocks.com has relied upon information supplied by its customers, public information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed.  Investors should not rely on the information contained in this website.  Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission ("SEC") and the Financial Industry Regulatory Authority ("FINRA").  Investors should use the information contained in this website or email as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Coolpennystocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.  Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Coolpennystocks Network has no obligation to update any of the information provided. Coolpennystocks Network, its owners, officers, directors, contractors and employees are not responsible for errors and omissions. From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our release or on our website may not have approved certain or any statements within the website or email.  Coolpennystocks encourages viewers to supplement the information obtained from this release and our website with independent research and other professional advice.  Coolpennystocks.com is not responsible for any claims made by the companies advertised herein, nor is Coolpennystocks.com responsible for any other promotional firm, its program or its structure.

By accessing, viewing, or using the website or communications originating from this release, you agree that Coolpennystocks, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Coolpennystocks, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content.  Links and access to these sites are provided for your convenience only.  Coolpennystocks uses third parties to disseminate information to subscribers.  Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to hold Coolpennystocks, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website or email is at your sole risk. Coolpennystocks disclaims all warranties of any kind, express or implied.